RE:ENDP Get real...the last chance for the shorts to cover. EPS 1,38 /Q2 is 5,52 per year, a steal around 20 bucks. All bad news out now.
- Second quarter 2016 revenue of $231.7 million, an increase of 1.4 per cent over the first quarter of 2016 and 208 per cent over the second quarter of 2015
- Reported second quarter GAAP net loss of $570.5 million, GAAP earnings per share loss of $11.18, which was primarily due to an adjustment to the carrying values of Nilandron® and Plaquenil® by $567 million due to generic competition
- Second quarter 2016 adjusted EBITDA1 of $142.3 million and adjusted earnings per share of $1.38
- Concordia's International segment launched 13 new products since October 21, 2015; the Company remains on track to meet its target of 60 plus launches in the next three years
- Revises 2016 guidance2 to US$859 million to US$888 million of revenue and adjusted EBITDA1 to US$510 million to US$540 million